Pediatric Department, Hospital "F. Del Ponte", University of Insubria, 21100 Varese, Italy.
Propaedeutics of Paediatrics No. 2, Communal Nonprofit Enterprise "City Children's Clinical Hospital # 19" of Kharkiv City Council, 61051 Kharkiv, Ukraine.
Nutrients. 2024 Mar 20;16(6):899. doi: 10.3390/nu16060899.
This multi-center prospective randomized controlled trial was a tolerance and safety study investigating the thickener locust bean gum (LBG) in infants with regurgitation, to support the re-evaluation of the safety of LBG in infant formula. The primary objective was to demonstrate that after an 8-week intervention, stool consistency was not inferior (i.e., was not looser or more watery) in infants fed an anti-regurgitation (AR) formula containing LBG vs. the stool consistency of infants fed with an unthickened control formula. A total of 103 full-term infants with regurgitation were randomized to the test or control formula. The test formula contained LBG (0.4 g/100 mL), short-chain galacto-oligosaccharides, and long-chain fructo-oligosaccharides (scGOS/lcFOS; 9:1; 0.4 g/100 mL) and postbiotics and the control formula contained scGOS/lcFOS (0.8 g/100 mL), the same amount of postbiotics, and did not contain LBG. The average stool consistency score at the 8th intervention week was the primary outcome parameter. Secondary outcome parameters were stool consistency at other timepoints, stool frequency, Infant Gastrointestinal Symptom Questionnaire (IGSQ) score, growth, (serious) adverse events ([S]AEs), regurgitation severity, and infant well-being. Overall, the infants were 36.9 ± 12.9 [mean ± SD] days old, 62.7% girls in the test, and 50.0% girls in the control group. The primary analysis showed that the test group did not have looser or more watery stools than the control group. IGSQ sum scores decreased comparably in both groups. The frequency of regurgitation was significantly lower in the test group compared to the control group (mixed model repeated measurement, ≤ 0.028) and parent-reported well-being scores were favorable. Adequate growth was observed in both groups. Both products were well-tolerated and safe and the AR formula with LBG was efficacious in reducing regurgitation frequency. This study provides further evidence for the dietary management of regurgitation by LBG-containing formulae in infants who are not exclusively breastfed, and the reassurance it can bring to parents.
这项多中心前瞻性随机对照试验是一项耐受性和安全性研究,旨在调查反流婴儿中增稠剂刺槐豆胶(LBG)的情况,以支持重新评估 LBG 在婴儿配方奶粉中的安全性。主要目的是证明在 8 周干预后,喂食含有 LBG 的抗反流(AR)配方奶粉的婴儿的粪便稠度与喂食未增稠对照配方奶粉的婴儿的粪便稠度没有差异(即不更稀或更水样)。共有 103 名患有反流的足月婴儿被随机分配到试验或对照配方组。试验配方含有 LBG(0.4 g/100 mL)、短链半乳糖寡糖和长链果糖寡糖(scGOS/lcFOS;9:1;0.4 g/100 mL)和后生元,对照配方含有 scGOS/lcFOS(0.8 g/100 mL)、相同数量的后生元和不含 LBG。第 8 周干预时的平均粪便稠度评分是主要的结局参数。次要结局参数包括其他时间点的粪便稠度、粪便频率、婴儿胃肠道症状问卷(IGSQ)评分、生长、(严重)不良事件(SAEs)、反流严重程度和婴儿健康状况。总体而言,婴儿的平均年龄为 36.9 ± 12.9 [平均值 ± 标准差] 天,试验组中女孩占 62.7%,对照组中女孩占 50.0%。主要分析表明,试验组的粪便没有比对照组更稀或更水样。两组的 IGSQ 总分均有可比性下降。与对照组相比,试验组的反流频率显著降低(混合模型重复测量,≤0.028),且家长报告的婴儿健康状况评分良好。两组均观察到生长良好。两种产品均具有良好的耐受性和安全性,含 LBG 的 AR 配方在降低反流频率方面有效。这项研究为非纯母乳喂养婴儿的 LBG 配方在反流的饮食管理方面提供了进一步的证据,并为父母带来了安心。